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Abstract Infection prevention is a key component of care and
an important determinant of clinical outcomes in a diverse
population of immunocompromised hosts. Vaccination re-
mains a fundamental preventative strategy, and clear guide-
lines exist for the vaccination of immunocompromised indi-
viduals and close contacts. Unfortunately, adherence to such
guidelines is frequently suboptimal, with consequent missed
opportunities to prevent infection. Additionally, vaccination
of immunocompromised individuals is known to produce
responses inferior to those observed in immunocompetent
hosts. Multiple factors contribute to this finding, and devel-
oping improved vaccination strategies for those at high risk of
infectious complications remains a priority of care providers.
Herein, we review potential factors contributing to vaccine
outcomes, focusing on host immune responses, and propose a
means for applying modern, innovative systems biology tech-
nology to model critical determinants of vaccination success.
With influenza vaccine in solid organ transplants used as a
case in point, novel means for stratifying individuals using a
host “immunophenotype” are explored, and strategies for
individualizing vaccine approaches tailored to safely optimize
vaccine responses in those most at risk are discussed.
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Introduction: Current Status of Vaccination
in Immunocompromised Hosts
Infectiousmorbidity andmortality remains a perpetual threat to
a diverse array of immunocompromised patient cohorts [1, 2].
Such groups are disproportionately affected by infection,
which can accelerate or precipitate adverse disease processes,
positioning vaccination as a key intervention [3]. “At-risk”
cohorts are many and include the elderly, neonates, pregnant
women, recipients of haematopoietic stem cell or solid organ
transplants (SOTs), HIV-infected patients, recipients of the
myriad of cytotoxic chemotherapies or biologic therapies,
and individuals suffering from comorbid conditions with im-
munosuppression as a consequence (e.g., obesity, diabetes
mellitus, end-stage organ failure, primary immunodeficiencies,
autoimmune diseases) [4-8].
Variability of the Immune Response
The observed “phenotypes” of immunosuppression are highly
diverse with regard to severity, the specific immunological
This article is part of the Topical Collection on Transplant and Oncology
D. O’Shea
Division of Infectious Diseases, University of Alberta,
Edmonton, Canada
D. O’Shea
Li Ka Shing Institute of Virology, University of Alberta,
Edmonton, Canada
L. A. Widmer : J. Stelling
Department of Biosystems Science and Engineering (D-BSSE),
ETH Zurich, Basel, Switzerland
L. A. Widmer : J. Stelling
Swiss Institute of Bioinformatics, Basel, Switzerland
A. Egli (*)
Infection Biology, Department Biomedicine, University of Basel,
Hebelstrasse 4, 4031 Basel, Switzerland
e-mail: a.egli@usb.ch
A. Egli
Clinical Microbiology, University Hospital of Basel, Basel,
Switzerland
Curr Infect Dis Rep (2014) 16:420
DOI 10.1007/s11908-014-0420-2
signaling cascades involved, and the resulting functional def-
icits. Therefore, patients from such cohorts merit an individ-
ualized approach to addressing the specific “type” of defect to
mitigate the negative consequences of infection where possi-
ble. Medical interventions to prevent infection take many
forms, including the use of prophylactic antimicrobials [9],
preemptive monitoring for the emergence of an infection [10],
and most important, vaccination. Since first employed as a
technique, vaccination has evolved into a powerful strategy
for preventing and, in some cases, eradicating human diseases
[11-13]. As is discussed later in more detail, “at-risk” popula-
tions consistently generate vaccine-specific immune re-
sponses that are considerably weaker than those of healthy
immunocompetent individuals. Optimizing vaccination by
using personalized strategies based on clinical, laboratory,
and even computational data may help to select patients at
risk for vaccine failure and specifically tailor vaccination
approaches.
The broad principles of vaccination for prevention apply
equally to all the risk groups listed above. After considering
the immunosuppressive conditions, vaccinations should be
optimized as early as possible following initial engagement
of the individual with the health-care system and repeated as
recommended [14, 15•]. Additional protection can be
achieved via recommendations to vaccinate family members
and health-care workers [14, 15•]. Despite the existence of
clear guidance, there remains considerable variability in clin-
ical practice, with many unfounded concerns continuing to
undermine optimal vaccination [16, 17].
From an immunological perspective, mounting an efficient
and protective vaccine-induced immune response involves a
highly complex interplay of numerous cellular and noncellular
immune components. Following vaccination of healthy vol-
unteers, it was shown that in peripheral blood mononuclear
cells and plasmablasts, several hundred gene-transcripts were
significantly altered in their expression [18, 19]. Additionally,
the intricate orchestration of the immune response is depen-
dent on the cytokine microenvironment created by migration
of activated cells (e.g., transfer of activated monocytes from
muscle to lymph nodes), as well as host single nucleotide
polymorphisms modulating individual signaling pathways
[20, 21•, 22-26]. Even more complexity is added by
immunosenescence [27-29], hormonal differences between
genders, circadian and monthly hormonal shifts [30, 31],
specific vaccine-related differences (type of application [32],
adjuvant use [33]), and types of pharmacologic immunosup-
pression [34, 35]. All these factors combine to generate a
complex biological system. Differences arising in any of these
factors may account for the high heterogeneity of vaccine-
induced immune responses, providing a rationale for examin-
ing determinants more critically to identify the fundamental
components of vaccine success—in particular, those
pertaining to immunocompromised individuals.
Surrogates of Vaccine-Induced Immune Response
Convention directs that antibody production is the primary
measure of vaccine efficacy and correlates with clinical pro-
tection via activity to neutralize pathogens or pathogenic toxin
in an extracellular state. This dependence on antibody is
widely debated, and recently the importance of cell-
mediated immunity after vaccination has been proposed [36].
Clinical protection has been correlated to adequate levels of
antibody production for various reasons. First, neutralizing an-
tibodies are capable of inhibiting infection [37-39]. Second,
antibody titers specifically associated with protection from in-
fection have been defined—for example, influenza
seroprotection with a titer above 1:40 or seroconversion with a
greater than fourfold pre- to postvaccine titer increase [40].
Indeed,meeting such humoral targets heavily influences vaccine
design, which primarily seeks to induce an antibody response.
Inactivated subunit vaccines appropriate for use in immu-
nosuppressed hosts such as polysaccharide, protein, or naked
DNAvaccines are safer, but less immunogenic and reactogenic
[41, 42]. The induced immune response against such vaccines
predominantly targets structural proteins, which represent ide-
al targets for antibodies. Nonstructural proteins, however, are
not fully expressed and are, thus, immunologically neglected.
Indeed, during “natural” infection, nonstructural proteins may
act to induce a potent cytotoxic T-cell response, and it is highly
likely that the development of a robust protective response
requires more than antibodies alone [43]. Live vaccines in use,
although contraindicated for the most part in the immunocom-
promised, represent an ideal stimulus. They provide both
structural and nonstructural antigens and generate broad, ro-
bust host responses and durable protection against infection. In
this context, antibody production represents but one quantifi-
able outcome of a highly complex process.
Cellular-based immune assays exist, which can provide
more detailed information on the complex interaction of den-
dritic cells, monocytes, and T- and B-cells. However, mea-
surements of activation markers on cells and intracellular
cytokine production or monitoring of cytokine expression
profiles requires specific laboratory equipment, is labor inten-
sive, and has not been established in routine clinical settings.
In reality, the true correlate of protection remains undefined
and is likely to vary on the basis of the pathogen and host–
pathogen interaction [36].
In this review article, we will utilize SOT recipients and
influenza vaccination as a model to address key issues
pertaining to vaccination in immunocompromised hosts.
Indefinite immunosuppression and the present reliance on
annual influenza vaccination considerably undermine the lev-
el of protection that can be achieved. Concluding, we will
address potential future strategies for monitoring vaccine re-
sponses, applying a “systems biology” approach to advance
personalized vaccination.
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Influenza Vaccine in Solid Organ Transplant Recipients
In SOT recipients, higher morbidity and mortality rates, as
compared with healthy individuals, have been reported during
infection with influenza [1]. Specifically in lung transplant
recipients, influenza may cause bronchiolitis obliterans syn-
drome and allograft rejection after lung transplantation and,
thereby, reduce graft survival significantly [44-46]. Since the
H1N1 pandemic of 2009, influenza vaccine responses in SOT
recipients have been extensively characterized. Across differ-
ent populations and different administration protocols, it was
clear that seroprotection and seroconversion to influenza vac-
cine lagged considerably behind rates observed in the immu-
nocompetent [47-49]. Quoted rates of seroprotection range
from 20 % to 60 % [50-53]. Thus, current influenza vaccine
practices would seem to be inadequate, most notably in indi-
viduals at risk. Influenza vaccine suffers from the need for
annual administration and annual antigen adjustment guided
by prevailing or predicted antigenic strains. This limitation is
further heightened by administration to patients under active
immunosuppression, which acts to compound a lack of
immunogenicity.
Vaccine-Induced T- and B-Cell Responses After
Transplantation
Dissecting the pathways from antigen recognition and deliv-
ery through uptake (by antigen presenting cells) and presen-
tation to T-cells directing cell-mediated and humoral immune
responses positions dendritic cells at the crucial interface
between innate and adaptive immune responses. Adequate
protection against intracellular pathogens may also be more
reliant on cell-mediated responses, and CD4 help itself is
integral to robust B-cell responses. The interplay between
key cellular components is complex and is outlined in
Fig. 1. Humoral responses aside, influenza vaccine has been
shown to induce potent influenza-specific CD4 T helper cells
(Th1 and Th2) and T follicular helper cells (TFH) [54, 55].
Indeed, McElhaney et al. proposed that cytokine expression
profiles and T-cell proliferation in response to Influenza anti-
gen was, in fact, indicative of protection in elderly adults [56].
Likewise in a HIV cohort, the baseline frequency of naïve
CD4 T-cells correlated directly with seroconversion.
Interestingly, this frequency of naïve T-cell populations was
inversely correlated with age [57]. Thus, baseline integrity of
immune cell populations significantly determines vaccine
outcomes, and this effect likely magnifies with age. Th2 and
TFH cytokines in particular are important cofactors for suc-
cessful vaccination, since these cytokines are critical for B-cell
activation and stimulation [58-61, 62••, 63, 64]. Although Th1
and cytotoxic T-cell responses are induced during vaccination
[65], their frequency and function has not been consistently
linked to antibody induction [66]. Thus, the critical
determinants of vaccine responses and clinical protection have
yet to be conclusively determined, and in immunocompro-
mised hosts in particular, quantitative antibody measurements
are an imperfect gauge.
Vaccine recipients can be broadly clustered into three
groups based on their antibody responses, which, in turn, are
dependent on respective helper T-cell cytokine expression and
the resulting B-cell activation states:
1. patients with high baseline seroprotection (already
seroprotected, no formal seroconversion achievable,
memory phenotype),
2. patients with inducible seroconversion (pre- to
postvaccine >4-fold antibody increase, priming/naïve
phenotype), and
3. nonresponsive patients with low seroprotection and no
seroconversion (anergic phenotype).
The Impact of Immunosuppression on Vaccine-Induced
Immunity
Immunosuppressive drugs significantly decrease vaccine re-
sponsiveness. Several studies have shown that mycophenolate
mofetil (MMF) [34, 67, 68] and sirolimus [69, 70] reduce the
immunogenicity of influenza vaccine. Although both drugs
are classical “antiproliferative” immunosuppressive drugs,
their modes of action differ in terms of how they modify
signaling pathways and the resulting phenotypes [71]. MMF
causes a dose-dependent reduction in proliferation of stimu-
lated B-cells [72]. MMF has been shown to inhibit B-cell
activation and proliferation and plasma cell formation [35,
73•]. In addition, MMF preferentially reduces virus-induced
Th2 cytokine expression, relative to that of Th1 cytokines
[74]. Aside from these recent findings, the effect of most
immunosuppressive drugs on vaccine responses remains
unknown.
Current Strategies to Improve Vaccine Responses
in Transplant Recipients
The marked impairment in vaccine responses in SOT cohorts
is akin to the experience in the vaccination of individuals over
the age of 65 against influenza and Streptococcus
pneumoniae. Antibody titers were lower, and there was little
protection afforded from pneumonic illness [75-77].
In efforts to overcome poor vaccine immunogenicity, var-
ious strategies have been proposed or attempted in immuno-
compromised groups with divergent outcomes.
1. Higher antigen load: Providing a higher dose of influenza
antigen per vaccination or the use of booster doses is
believed to lead to increased follicular dendritic cells
loadedwith antigen in lymph nodes capable of prolonging
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B-cell stimulation. Results from such strategies have been
mixed and in an HIV cohort, Cooper et al. investigated the
use of a higher influenza antigen load, but this did not
significantly alter the rates of seroprotection [78].
Similarly, high-dose vaccine in an SOT cohort did not
achieve higher seroconversion [51]. In an elderly popula-
tion, however, high-dose vaccine did, in fact, increase
seroconversion rates [79].
2. Altered route of administration: Theoretically, intradermal
vaccination carries benefits of improved immunogenicity
via direct and enhanced stimulation of Langerhans cells
and the subsequent priming of cell-mediated and humoral
immune responses. Again, in a recent randomized con-
trolled trial, Baluch et al. found no significant difference
in influenza seroconversion rates comparing high-dose
intradermal with standard intramuscular vaccination in a
cohort of SOT recipients [53].
3. Use of adjuvants: Adjuvants are widely employed in
vaccination, acting to nonspecifically stimulate the local
innate immune response, thus heightening ultimate hu-
moral responses [33]. Aluminium salts and squalene-
based oil-in-water emulsions are the two primary agents
in general use. They promote increased cellular traffick-
ing, with improved antigen uptake and presentation [33].
Surveillance of the adjuvanted pandemic H1N1 vaccines
demonstrated improved rates of seroconversion even in
the immunocompromised. Dhedin et al. more recently
reported humoral responses with an adjuvanted influenza
vaccine equivalent to that observed in natural infection
[80]. In contrast, Manuel et al. reported that despite adju-
vants and a double-dosage regimen, humoral responses
remain significantly impaired in SOT recipients [81].
Novel adjuvants such as TLR agonists are emerging as a
means to even more specifically and potently stimulate
the host immune response. Concerns arise, however, in
relation to this potency, with potential consequences of
overstimulation of innate responses leading to poor toler-
ability and high rates of adverse reactions. Specific to
SOT recipients, it has been proposed that the use of potent
adjuvants can give rise to the generation of allo-antibody
and result in an increased risk of allograft rejection [82].
To date, such concerns regarding rejection have not been
substantiated [83, 84]; thus, adjuvanted vaccines, partic-
ularly in those with impaired host responses, represent a
valid means by which to advance vaccination. Even more
attractive is the ability to specifically boost the immune
component often lacking in cohorts such as SOT recipi-
ents or the elderly. A means for tailoring host responses to
Fig. 1 Interaction of vaccine-stimulated immune cells in the context of
transplantation. Virus-specific B-cells receive important growth factors
and cytokines from T-cells and monocytes. In response, antigen
presentation is increased in a feedback loop. The activation of T-cells is
strongly modulated by co-stimulatory signals (such as CD28/CD86 or
PD1L/PD1) and immunosuppressive drugs
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favor Th2-mediated stimulation of B-cells stands to spe-
cifically overcome the deficits identified in such hosts: an
impairment of the extent and diversity of proliferative
adaptive responses [75].
“Next-Generation” Strategies to Improve Vaccine
Responses in Transplant Recipients
Novel Types of Vaccines and Adjuvants
A number of innovative technological advances are being
applied to vaccination to improve existing vaccines and to
develop new vaccines against existing and emerging patho-
gens. Recently, vaccines using recombinant protein technolo-
gy and containing highly conserved regions of influenza A
virus have demonstrated immunogenicity and cross-reactive
potential, offering an option to move away from annual influ-
enza vaccination and provide cross protection against novel
assortments [85, 86]. One such vaccine, however, was highly
dependent on the use of an adjuvant in the form of flagellin, a
Toll-like receptor (TLR)-5 agonist, to generate sufficient im-
munogenicity [85].
Other novel technologies include the use of nanoparticles
[87], vector-based vaccines, and nucleic acid vaccines [88,
89]. Theoretically, these systems can deliver prolonged anti-
gen release and multiple antigens, perhaps a situation more
akin to that occurring during natural infection. To date, how-
ever, challenges continue to exist in the form of stability,
cytotoxicity, and durable immunogenicity, as demonstrated
by the need for a potent adjuvant in the influenza vaccine
example above. Likewise, DNA vaccines are limited, due to
the requirement for multiple administrations, and vector-based
approaches, due to the development of host immunity
targeting the vector [88].
In addition to redesigned vaccines, novel types of adju-
vants selectively targeting specific immune signaling cascades
may be used for high-risk patient cohorts. Although TLR-
agonists may be potent inducers of Th1 immune responses,
for antibody-based vaccines, this may not be the right strategy
[33]. Safety issues in terms of triggering rejection episodes
have to be carefully assessed and explored in all novel adju-
vant approaches. Temporally triggering Th2 immune re-
sponses could conceivably induce a more specific B-cell and
antibody response—which may, for example, be safer in
transplant recipients.
Personalizing Vaccination with Genetic Risk Profiling
The identification of single nucleotide polymorphisms (SNPs)
associated with postvaccine phenotypes carries potential for
application to the individualization of vaccination strategies.
To date, no genome-wide association studies (GWASs)
addressing vaccination have been performed in transplant
recipients. To the best of our knowledge, GWASs have been
conducted focusing only on anthrax [90], small pox [23, 91,
92], HIV [93], and Hepatitis B virus [94]. However, these
studies were relatively small, and vaccine failure for these
vaccines in an otherwise healthy population is often low.
Therefore, these studies might have been underpowered.
One GWAS explored the association of SNPs with side effects
from vaccines [95].
A more focused study addressing a number of innate
immune-associated genes has been undertaken with respect
to measles vaccination. In immunocompentent children, 12
antiviral genes from innate signaling cascades (of 307 evalu-
ated genes, including, among others, RIG-I, Interferon-
induced GTP-binding protein Mx1 [Mx1], 2'-5 '-
oligoadenylate synthetase 1 [OAS1]) showed genetic variants,
which were associated with measles-specific antibody titer
variations [96•, 97]. In particular, SNPs in the Interferon-λ
signaling cascade (IFNL3) were associated with twofold
higher postvaccine titers [96•]. Polymorphisms in the region
encoding this most recently identified Interferon family have
been strongly associated with host responses to hepatitis C
virus [98-100]. Emerging data implicate IFN-λ as an innate
cytokine modulating the balance in helper T-cell responses;
thus, such SNPs can have important influences on vaccine
responses [101-103]. In the near future, patients identified as
carrying “risk” polymorphisms could be vaccinated with dif-
ferent protocols, with increased dosages, different application
routes, or vaccines containing adjuvants that may compensate
for a specific immune defect in a more safe and targeted
manner.
Stratifying Host Factors to Individualize Vaccine
Strategies in Transplant Recipients Using Computational
Modeling
As was previously discussed, vaccine responses in transplant
recipients will vary due to multiple host-, vaccine-, and
transplant-related factors (Fig. 2). It is clear from the body
of evidence available that the strength and quality of the
response to vaccination is a composite of the quality of
antigen (immunogenicity, broadly conserved epitopes) used
to emulate the pathogen and the integrity of the host response.
The host factors involved during a vaccine response include
all aspects of “–omics,” such as genomics, proteomics, and
metabolomics [104•, 105-107]. The resulting host-dependent
immune reactions are driven by the highly complex spatio-
temporal interplay between signaling pathways, cells, and
tissues—a prime target for systems biology modeling
approaches.
Computationally modelling the dynamic response of the
immune system is a challenging task even without taking host
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variability into account. Mathematical models that focus on
cell-to-cell interactions in the immune system range from
highly abstracted representations of immune and target cells
[108] to more detailed ones that, for example, distinguish
between B- and T-cells [109]. However, most of these models
represent the system rather at the level of phenomenological
interactions between subpopulations of immune cells, and not
mechanistically. This holds also for the most advancedmodels
in which various immune cell subpopulations are integrated
on the basis of previous models [110]. Overall, as was shown
recently by a comparative study of mathematical models
describing immune responses to influenza infection, the pre-
dictive ability of different, state-of-the-art immunological
models is rather limited; it appears that the system behaviors
captured are largely dictated by the data sets used for model
calibration, with additional biases because human experimen-
tal data are scarce [111].
In contrast to the models outlined above, systems biology
models were developed primarily to understand molecular
mechanisms in single signaling pathways of importance to
the immune system. These approaches allowed for detailed
insight into, for example, T-cell receptor signaling and the
mechanistic foundations of T-cell memory [112••]. In other
cellular contexts, for example, detailed mechanistic models
have been developed to capture the dynamics of interferon
signaling from the receptor to target genes such as antiviral
genes. Model-based analyses of molecular signaling
mechanisms have been published for type I [113•, 114] and
II [115], but not yet for type III Interferons. In principle, such
molecular-level computational models based on in vitro or
in vivo data allow manipulation of variables of interest (e.g.,
genomic variation) and the determination of downstream ef-
fects [112••, 116, 117].
In transplant recipients, examples of such variables of
interest for simulation-based analysis of factor influences
are given in time since transplantation, allograft type, and
immunosuppressive treatments (dose and serum peak/trough
levels). The effects introduced by exogenous immunosup-
pression are particularly influential in SOT recipients, where
initial intensive immunosuppression—which is then main-
tained at a basal level—strongly impacts immune response
in general and vaccine responsiveness in particular (Fig. 3).
In order to extend quantitative models of an immune response
to transplant recipients, the mechanisms and extent of immu-
nosuppression have to be quantified accurately; such studies
do not exist to date.
The innate immune response is the first step of the signal
cascade and likely assumes even more importance in SOT
recipients with regard to triggering downstream priming of T-
and B-cells [118-120]. Therefore, to explore variable out-
comes (for example, seroprotection or seroconversion) prior
to vaccination using clinical or immunological parameters,
systems biology and immunology models need to be ultimate-
ly integrated into multilevel frameworks as used in oncology
Fig. 2 Factors modulating
vaccine-stimulated immune
responses. These factors should
be implemented into
computational models for
clinical usages
420, Page 6 of 11 Curr Infect Dis Rep (2014) 16:420
[121]. Only the integration of population-level and mechanis-
tic models will allow linkage of genotypes such as SNPs in
specific signaling pathways with clinical outcomes in a pre-
dictive manner.
Finally, computational immunology has barely addressed
the problem of systematic estimations of interindividual var-
iability from in vivo, clinical data, because many fundamental
studies were carried out in vitro. However, such analysis is
required to generate patient-specific predictions. In related
fields such as pharmacokinetics, the standard methodological
approach is to employ nonlinear mixed effect models—that
is, models that capture common mechanisms (fixed effects)
as well as variability between individuals (or subgroups of the
population; so-called random effects) [122]. Calibrating these
type of models to experimental in vitro or clinical data,
however, faces important computational challenges and usu-
ally requires small-scale models [123]. This currently ham-
pers progress toward the ideal of patient-specific vaccine
optimization using purely computational predictions.
Despite these important considerations, prediction of vaccine
responses based on system-wide measures is achievable, but
challenges remain for robust population-wide predictions
based only on prevaccination measures, especially in partially
efficacious vaccines such as that for influenza. In the future,
further research in this fast evolving field is required to
extract the maximum potential from these technological ad-
vances providing a unique insight into determinants of pro-
tection and selecting out individuals for a tailored vaccine
schedule or to identify key immunologic cascades for
targeted adjuvants.
Summary and Outlook
The field of vaccination is highly active and substantiates the
medical professionmandate to strive for disease prevention. In
that regard, efforts should be directed to those most at risk—
namely, immunocompromised individuals. Many novel ad-
vances are entering into clinical trial stages, and these provide
hope for both an improved and a broader spectrum of vaccine
options in the future. While delivery methods remain vitally
important, the host response to vaccination is a critical deter-
minant of outcome. In particular in relation to immunocom-
promised hosts, a window exists to vaccinate early in the
clinical care pathway to optimize the chance of success.
However, the efficacy of annual influenza vaccination in
heavily immunocompromised hosts draws the challenges into
sharp focus. Until a “universal influenza vaccine” is realized
in clinical practice, it is imperative that we devise strategies to
boost response to existing vaccines by individualizing vaccine
schedules or using existing or new adjuvants. Allied to this is
further research into the immune cascades determining vac-
cine efficacy, taking advantage of systems biology and math-
ematical modeling approaches that could ultimately enable
individualized vaccination strategies to optimally protect the
most vulnerable hosts against disease.
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